FAMVIR Drug Patent Profile
✉ Email this page to a colleague
When do Famvir patents expire, and when can generic versions of Famvir launch?
Famvir is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in FAMVIR is famciclovir. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the famciclovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Famvir
A generic version of FAMVIR was approved as famciclovir by TEVA PHARMS on August 24th, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FAMVIR?
- What are the global sales for FAMVIR?
- What is Average Wholesale Price for FAMVIR?
Summary for FAMVIR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 137 |
| Clinical Trials: | 7 |
| Patent Applications: | 4,190 |
| DailyMed Link: | FAMVIR at DailyMed |
Recent Clinical Trials for FAMVIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| House Research Institute | Phase 3 |
| House Clinic, Inc. | Phase 3 |
| Novartis | Phase 2 |
Paragraph IV (Patent) Challenges for FAMVIR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| FAMVIR | Tablets | famciclovir | 125 mg, 250 mg and 500 mg | 020363 | 1 | 2004-12-28 |
US Patents and Regulatory Information for FAMVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-003 | Dec 11, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-001 | Apr 26, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-002 | Jun 29, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FAMVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-002 | Jun 29, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-002 | Jun 29, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-003 | Dec 11, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-003 | Dec 11, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-003 | Dec 11, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-001 | Apr 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | FAMVIR | famciclovir | TABLET;ORAL | 020363-001 | Apr 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FAMVIR
See the table below for patents covering FAMVIR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 216885 | ⤷ Sign Up | |
| Israel | 111138 | PHARMACEUTICAL COMPOSITIONS COMPRISING PENCICLOVIR AND/OR ITS BIOPRECURSOR AND/OR ITS DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF POST-HERPETIC NEURALGIA | ⤷ Sign Up |
| Canada | 1339818 | DERIVES DE LA PURINE ANTIVIRAUX (ANTIVIRAL PURINE DERIVATIVES) | ⤷ Sign Up |
| Hungary | 9600882 | ⤷ Sign Up | |
| Canada | 2173505 | UTILISATION DE LA PENCICLOVIR DANS LE TRAITEMENT DE NEVRALGIE POST-HERPETIQUE (USE OF PENCICLOVIR FOR THE TREATMENT OF POST-HERPETIC NEURALGIA) | ⤷ Sign Up |
| United Kingdom | 8423833 | ⤷ Sign Up | |
| African Regional IP Organization (ARIPO) | 9400684 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FAMVIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0141927 | SPC/GB96/014 | United Kingdom | ⤷ Sign Up | SPC/GB96/014: 20040810, EXPIRES: 20090809 |
| 0141927 | 97C0033 | Belgium | ⤷ Sign Up | PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: 981 IS 110 F 7; 19970206; FIRST REGISTRATION: GB 10592/0078 19960228 |
| 0182024 | SPC/GB94/002 | United Kingdom | ⤷ Sign Up | SPC/GB94/002: 20050910, EXPIRES: 20081209 |
| 0053902 | 96C0036 | Belgium | ⤷ Sign Up | PRODUCT NAME: FAMCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21325 19960708; FIRST REGISTRATION: GB - 10592/0035 19931210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
